Radius Health
Global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $890m Valuation: $890m 0.3x EV/Revenue 3.9x EV/EBITDA | Buyout | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 40 % | (10 %) | (20 %) | 61 % | 26 % | (17 %) | (5 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 8 % | 6 % | 1 % | 8 % | 7 % | 1 % | 1 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | 3 % | - | 6 % | 5 % | (1 %) | (10 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Radius Health, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing innovative endocrine therapeutics. The company primarily serves patients suffering from osteoporosis and breast cancer, aiming to address significant unmet medical needs in these areas. Operating in the healthcare and pharmaceutical markets, Radius Health employs a business model that spans from drug discovery and development to commercialization. Revenue is generated through the sale of its FDA-approved products, as well as through strategic partnerships and collaborations with other pharmaceutical companies. The company's flagship product, abaloparatide, is a treatment for osteoporosis, and it continues to advance its pipeline with new therapeutic candidates. Radius Health is committed to scientific excellence and improving patient outcomes through its innovative therapies.
Keywords: biopharmaceutical, endocrine therapeutics, osteoporosis, breast cancer, drug discovery, commercialization, abaloparatide, FDA-approved, patient outcomes, strategic partnerships.